ABIVAX Société Anonyme ABVX
88.71 USD +3.80 (+4.48%)
At closeNov 4, 2026, 7:55 AM EST
90.47 +1.76 +1.98%
Pre-market · Nov 4, 7:55 AM ET
85.26 Day range 90.12
69.81 52-week range 148.83
- YTD
- -34.22%
- 1 year
- -10.26%
- Market cap
- 7.77B
- Revenue (ttm)
- 4.67M
- EPS (ttm)
- -6.08
- Shares out
- 87.54M
- Forward P/E
- -23.13
- YTD return
- -34.22%
- 1-year return
- -10.26%
- Volume
- 585.03K
- Avg volume
- 1.09M
- Open
- 85.37
- Previous close
- 84.91
- Day's range
- 85.26 – 90.12
- 52-week range
- 69.81 – 148.83
- Beta
- -0.34
- Analysts
- Strong Buy
- Price target
- 163.58 (+84.4%)
- Earnings date
- Dec 21, 2026
3M -36.48 (-29.14%)
Key statistics
- Enterprise value
- 6.38B
- PEG ratio
- 0.00
- Price / sales
- 1663.63
- Price / book
- 17.21
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -6.80%
- Free cash flow
- -125.90M
- Total cash
- 402.38M
- Total debt
- 1.21M
- Return on equity
- -252.35%
- Short % of float
- 8.39%
- 50-day average
- 99.53
- 200-day average
- 113.94
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 163.58 +84.4% upside
Now 88.71
- Target (low)
- 142.00
- Target (mean)
- 163.58
- Target (high)
- 181.00
Ratings (0m) 12 12 buy · 0 hold · 0 sell
- Strong buy4
- Buy8
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 21, 2026
Expected Dec 21, 2026. Consensus EPS estimate -0.85675.
Financials — quick view
ABVX Revenue — quarterly 1.20M
ABVX Net income — quarterly -117.43M
ABVX EPS — quarterly -1.47
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 21, 2026 | Sep 30, 2026 | -0.9199 | — | — | — |
| Sep 21, 2026 | Jun 30, 2026 | -0.97553 | -1.71 | -0.73 | -75.29% |
| May 22, 2026 | Mar 31, 2026 | -1.07 | -0.71 | +0.36 | +33.64% |
| Mar 23, 2026 | Dec 31, 2025 | -1.70 | -1.19 | +0.51 | +30.00% |
| Dec 15, 2025 | Sep 30, 2025 | -0.78649 | -2.47 | -1.69 | -214.27% |
| Sep 8, 2025 | Jun 30, 2025 | -0.90 | -0.86 | +0.04 | +4.44% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | Wedbush | main | Neutral | Neutral |
| Oct 20, 2026 | Guggenheim | reit | Buy | Buy |
| Sep 22, 2026 | Truist Securities | main | Buy | Buy |
| Sep 22, 2026 | Wedbush | main | Neutral | Neutral |
| Sep 22, 2026 | Barclays | main | Overweight | Overweight |
| Sep 10, 2026 | Goldman Sachs | init | — | Buy |
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- Website
- abivax.com
News
Abivax to Participate in Upcoming Fall Investor Conferences 
10 Health Care Stocks Whale Activity In Today’s Session 
Wedbush Maintains Neutral on Abivax, Lowers Price Target to $96 
10 Health Care Stocks With Whale Alerts In Today’s Session 
Abivax To Present Seven Scientific Abstracts On Obefazimod, Lead Drug Candidate For Treatment Of Active Ulcerative Colitis At UEG Week 2026 Meeting 
10 Health Care Stocks Whale Activity In Today’s Session - 10 Health Care Stocks With Whale Alerts In Today’s Session
- 10 Health Care Stocks Whale Activity In Today’s Session
These Analysts Slash Their Forecasts On Abivax Following H1 Results 
Truist Securities Maintains Buy on Abivax, Lowers Price Target to $151
Your note
Sign in to keep a note on ABVX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 6.86% | 6,007,834 | 532.95M | Jun 29, 2026 |
| Darwin Global Management, Ltd. | 4.14% | 3,621,583 | 321.27M | Jun 29, 2026 |
| Helikon Investments Ltd | 3.18% | 2,787,131 | 247.25M | Jun 29, 2026 |
| Vestal Point Capital, LP | 2.68% | 2,349,443 | 208.42M | Jun 29, 2026 |
| Jupiter Topco LLC | 2.19% | 1,913,933 | 169.78M | Jun 29, 2026 |
| UBS Group AG | 2.11% | 1,844,918 | 163.66M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ALGER INSTITUTIONAL FUNDS-Alger Focus Equity Fund | 0.69% | 607,577 | 53.90M | Jul 30, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.65% | 566,951 | 50.29M | Sep 29, 2026 |
| iShares Trust-iShares Core MSCI EAFE ETF | 0.56% | 492,838 | 43.72M | Sep 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 0.45% | 394,782 | 35.02M | Jun 29, 2026 |
| ALGER FUNDS II-Alger Spectra Fund | 0.38% | 334,177 | 29.64M | Jul 30, 2026 |
| HARBOR FUNDS-Harbor Small Cap Growth Fund | 0.34% | 296,560 | 26.31M | Jul 30, 2026 |